Edna Soares

Dr. Edna Soares

University of Coimbra, Center for Innovative Biomedicine and Biotechnology (CIBB), Coimbra, Portugal
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2020 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
PDF file
SJSandra Jesus
Sandra Jesus
AMAna Patrícia Marques
Ana Patrícia Marques
ADAlana Duarte
Alana Duarte
ESEdna Soares
Edna Soares
JPJoão Panão-Costa
João Panão-Costa
OBOlga Borges
Olga Borges
Nanoparticles (NPs) assumed an important role in the area of drug delivery. Despite the number of studies including NPs are growing over the last years, their side effects on the immune system are often ignored or omitted. One of the most studied polymers in the nano based drug delivery system field is chitosan (Chit). In the scientific literature, although the physicochemical properties [molecular weight (MW) or deacetylation degree (DDA)] of the chitosan, endotoxin contamination and appropriate testing controls are rarely reported, they can strongly influence immunotoxicity results. The present work aimed to study the immunotoxicity of NPs produced with different DDA and MW Chit polymers and to benchmark it against the polymer itself. Chit NPs were prepared based on the ionic gelation of Chit with sodium tripolyphosphate (TPP). This method allowed the production of two different NPs: Chit 80% NPs (80% DDA) and Chit 93% NPs (93% DDA). In general, we found greater reduction in cell viability induced by Chit NPs than the respective Chit polymers when tested in vitro using human peripheral blood monocytes (PBMCs) or RAW 264.7 cell line. In addition, Chit 80% NPs were more cytotoxic for PBMCs, increased reactive oxygen species (ROS) production (above 156 μg/mL) in the RAW 264.7 cell line and interfered with the intrinsic pathway of coagulation (at 1 mg/mL) when compared to Chit 93% NPs. On the other hand, only Chit 93% NPs induced platelet aggregation (at 2 mg/mL). Although Chit NPs and Chit polymers did not stimulate the nitric oxide (NO) production in RAW 264.7 cells, they induced a decrease in lipopolysaccharide (LPS)-induced NO production at all tested concentrations. None of Chit NPs and polymers caused hemolysis, nor induced PBMCs to secrete TNF-α and IL-6 cytokines. From the obtained results we concluded that the DDA of the Chit polymer and the size of Chit NPs influence the in vitro immunotoxicity results. As the NPs are more cytotoxic than the corresponding polymers, one should be careful in the extrapolation of trends from the polymer to the NPs, and in the comparisons among delivery systems prepared with different DDA chitosans.

1 October 2013 in Neuroscience
Verified
Journal Article
Closed access
ESEdna Soares
Edna Soares
RPR.D. Prediger
R.D. Prediger
SNSara Nunes
Sara Nunes
ACA.A. Castro
A.A. Castro
Sofia VianaSofia Viana
Sofia Viana
FPFrederico Pereira
Frederico Pereira

7 March 2013 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
SNSara Nunes
Sara Nunes
ESEdna Soares
Edna Soares
JFJoao Fernandes
Joao Fernandes
Sofia VianaSofia Viana
Sofia Viana
ECEugenia Carvalho
Eugenia Carvalho
Flávio ReisFlávio Reis
Flávio Reis
Background: Diabetic cardiomyopathy (DCM) is defined as structural and functional changes in the myocardium due to metabolic and cellular abnormalities induced by diabetes mellitus (DM). The impact of prediabetic conditions on the cardiac tissue remains to be elucidated. The goal of this study was to elucidate whether cardiac dysfunction is already present in a state of prediabetes, in the presence of insulin resistance, and to unravel the underlying mechanisms, in a rat model without obesity and hypertension as confounding factors. Methods: Two groups of 16-week-old Wistar rats were tested during a 9 week protocol: high sucrose (HSu) diet group (n = 7) – rats receiving 35% of sucrose in drinking water vs the vehicle control group (n = 7). The animal model was characterized in terms of body weight (BW) and the glycemic, insulinemic and lipidic profiles. The following parameters were assessed to evaluate possible early cardiac alterations and underlying mechanisms: blood pressure, heart rate, heart and left ventricle (LV) trophism indexes, as well as the serum and tissue protein and/or the mRNA expression of markers for fibrosis, hypertrophy, proliferation, apoptosis, angiogenesis, endothelial function, inflammation and oxidative stress. Results: The HSu-treated rats presented normal fasting plasma glucose (FPG) but impaired glucose tolerance (IGT), accompanied by hyperinsulinemia and insulin resistance (P < 0.01), confirming this rat model as prediabetic. Furthermore, although hypertriglyceridemia (P < 0.05) was observed, obesity and hypertension were absent. Regarding the impact of the HSu diet on the cardiac tissue, our results indicated that 9 weeks of treatment might be associated with initial cardiac changes, as suggested by the increased LV weight/BW ratio (P < 0.01) and a remarkable brain natriuretic peptide (BNP) mRNA overexpression (P < 0.01), together with a marked trend for an upregulation of other important mediators of fibrosis, hypertrophy, angiogenesis and endothelial lesions, as well as oxidative stress. The inflammatory and apoptotic markers measured were unchanged. Conclusions: This animal model of prediabetes/insulin resistance could be an important tool to evaluate the early cardiac impact of dysmetabolism (hyperinsulinemia and impaired glucose tolerance with fasting normoglycemia), without confounding factors such as obesity and hypertension. Left ventricle hypertrophy is already present and brain natriuretic peptide seems to be the best early marker for this condition.

1 December 2018 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
SJSandra Jesus
Sandra Jesus
ESEdna Soares
Edna Soares
Maria Teresa CruzMaria Teresa Cruz
Maria Teresa Cruz
OBOlga Borges
Olga Borges

1 May 2016 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
SJSandra Jesus
Sandra Jesus
ESEdna Soares
Edna Soares
JPJoão Panão-Costa
João Panão-Costa
GBGerrit Borchard
Gerrit Borchard
OBOlga Borges
Olga Borges

1 January 2018 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
ESEdna Soares
Edna Soares
SJSandra Jesus
Sandra Jesus
OBOlga Borges
Olga Borges